CDC reports on bivalent COVID-19 vaccine, Paxlovid effectiveness | AHA News
COVID-19 bivalent booster effectiveness in people with and without immune dysfunction L
Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study - The Lancet Infectious Diseases
COVID-19 BIVALENT BOOSTER EFFECTIVENESS IN PEOPLE WITH AND WITHOUT IMMUNE DYSFUNCTION - CROI Conference
Effectiveness of Bivalent Boosters against Severe Omicron Infection | NEJM
Vaccines | Free Full-Text | The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What
Effectiveness of Vaccination and Previous Infection Against Omicron Infection and Severe Outcomes in Children Under 12 Years of Age | medRxiv
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022 | MMWR
Bivalent COVID Shots May Hold Up Better Against Severe Omicron | MedPage Today
Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ
Updated COVID-19 booster targets subvariants responsible for 98% of cases today : Oregon Health News Blog
CDC publishes first estimates of bivalent boosters' effectiveness against XBB.1.5
Real-world data show new Covid boosters increase protection
Potentially breaking the COVID-19 stalemate with variant booster, bivalent or polyvalent vaccines
A quick update on the bivalent boosters - by Eric Topol
COVID-19 Bivalent Boosters | Johns Hopkins | Bloomberg School of Public Health
New Omicron-specific vaccines offer similar protection to existing boosters
Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ
A Bivalent Omicron-Containing Booster Vaccine against Covid-19 | NEJM
Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged ≥50 years in Ontario, Canada | medRxiv
Potentially breaking the COVID-19 stalemate with variant booster, bivalent or polyvalent vaccines
Why payers should be preparing now for new COVID-19 boosters
